Qiagen N.V. (NASDAQ:QGEN) – Research analysts at Jefferies Group lowered their Q3 2017 earnings per share estimates for Qiagen N.V. in a note issued to investors on Monday. Jefferies Group analyst P. Welford now forecasts that the company will post earnings of $0.31 per share for the quarter, down from their previous estimate of $0.32. Jefferies Group currently has a “Hold” rating and a $28.00 target price on the stock. Jefferies Group also issued estimates for Qiagen N.V.’s FY2017 earnings at $1.18 EPS and FY2018 earnings at $1.38 EPS.
Qiagen N.V. (NASDAQ:QGEN) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.02. The company had revenue of $349 million for the quarter, compared to analyst estimates of $353.09 million. Qiagen N.V. had a net margin of 5.44% and a return on equity of 10.98%. Qiagen N.V.’s revenue was up 4.4% compared to the same quarter last year. During the same period last year, the company posted $0.24 earnings per share. ILLEGAL ACTIVITY NOTICE: “Q3 2017 Earnings Estimate for Qiagen N.V. Issued By Jefferies Group (QGEN)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.com-unik.info/2017/08/12/q3-2017-earnings-estimate-for-qiagen-n-v-issued-by-jefferies-group-qgen-updated.html.
QGEN has been the topic of several other reports. DZ Bank AG restated a “neutral” rating on shares of Qiagen N.V. in a report on Monday, May 29th. Deutsche Bank AG reiterated a “buy” rating on shares of Qiagen N.V. in a report on Monday. Barclays PLC reiterated an “overweight” rating and set a $37.00 target price (up from $33.00) on shares of Qiagen N.V. in a report on Monday, July 17th. Commerzbank Ag reiterated a “buy” rating on shares of Qiagen N.V. in a report on Monday, May 29th. Finally, BidaskClub lowered shares of Qiagen N.V. from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Seven research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Qiagen N.V. presently has a consensus rating of “Hold” and an average target price of $33.19.
Qiagen N.V. (NASDAQ:QGEN) opened at 32.94 on Tuesday. The stock has a market capitalization of $7.44 billion, a price-to-earnings ratio of 96.88 and a beta of 1.15. The company’s 50-day moving average is $33.97 and its 200 day moving average is $31.03. Qiagen N.V. has a one year low of $24.86 and a one year high of $35.26.
Large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its stake in shares of Qiagen N.V. by 58.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 72,909 shares of the company’s stock worth $2,043,000 after buying an additional 26,838 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Qiagen N.V. by 49.4% in the fourth quarter. AQR Capital Management LLC now owns 64,175 shares of the company’s stock worth $1,801,000 after buying an additional 21,234 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of Qiagen N.V. by 4.4% in the fourth quarter. Teachers Advisors LLC now owns 238,461 shares of the company’s stock worth $6,682,000 after buying an additional 10,158 shares during the last quarter. Quadrant Capital Group LLC raised its stake in shares of Qiagen N.V. by 403.4% in the first quarter. Quadrant Capital Group LLC now owns 5,517 shares of the company’s stock worth $154,000 after buying an additional 4,421 shares during the last quarter. Finally, Capstone Asset Management Co. raised its stake in shares of Qiagen N.V. by 6.4% in the first quarter. Capstone Asset Management Co. now owns 74,130 shares of the company’s stock worth $2,148,000 after buying an additional 4,441 shares during the last quarter. Institutional investors and hedge funds own 60.45% of the company’s stock.
About Qiagen N.V.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
What are top analysts saying about Qiagen N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Qiagen N.V. and related companies.